Cannabis Europa is proud to announce Zenabis as our Lunch Partner for Cannabis Europa Paris on February 8th.
Zenabis is a significant licensed cannabis cultivator of medical and recreational cannabis in Canada, and employs staff coast-to-coast, across facilities in Atholville, New Brunswick; Delta and Langley, B.C.; and Stellarton, Nova Scotia. In addition to gaining technologically advanced knowledge of plant propagation, the recent addition of state of the art greenhouses in Langley provides Zenabis with 3.5 million square feet of facility space that can, upon full conversion, be dedicated to cannabis production space.
If all facility space is dedicated to production, Zenabis will own, and have access to, 660,000 square feet of high-quality indoor cannabis production space, as well as 2.1 million square feet of greenhouse space at its Langley facility, strategically positioned on Canada’s coasts. These facilities, if fully converted for cannabis production, would have the design capacity to yield 479,700 kg of dried cannabis annually, for both national and international market distribution. The Zenabis brand name is used among the medical space, while Namaste is used to service the recreational market.
Cannabis Europa is proud to welcome Zenabis to a growing list of Canadian companies that will present significant experience and know-how within the cannabis field. The Paris event on February 8th will be a chance to hear from companies like Zenabis who are at the forefront of the Canadian cannabis revolution which is currently leading the international market.
Team of Excellence
Rick Brar, Zenabis, Co-Founder & Special Advisor will be joining Cannabis Europa Paris as a Speaker.
The management team at Zenabis has significant experience in finance, agriculture, technology, pharmaceutical sales, consumer packaged goods, international distribution, and brand marketing. Leadership is backed by the expertise of a Chief Growing Officer, a Chief Science Officer, and Chief Medical Officer. As evidenced by letters of intent with strategic partners, and purchase orders with governments and distribution partners, Zenabis has been proven as a trusted and innovative cannabis front-runner.
As Canadian companies flourish on home-soil many of the top cultivators are looking at expansion plans in Europe.
How do investment opportunities in the European cannabis industry compare to that of North America, and how do they differ? What is Canada’s first-mover advantage within Europe’s growing industry, and will we see a European cannabis powerhouse catalyse soon? We look forward to seeing you on February 8th at Maison de la Chimie for vibrant discussions on these and many other questions pertaining to the future of medical cannabis in Europe.
